

Finnian R Mc Causland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2537671/publications.pdf>

Version: 2024-02-01

72
papers

3,812
citations

304743

22
h-index

144013

57
g-index

72
all docs

72
docs citations

72
times ranked

6855
citing authors

#	ARTICLE	IF	CITATIONS
1	Dialysis Dose and Intradialytic Hypotension: Results from the HEMO Study. American Journal of Nephrology, 2013, 38, 388-396.	3.1	1,883
2	Circulating Mitochondrial DNA in Patients in the ICU as a Marker of Mortality: Derivation and Validation. PLoS Medicine, 2013, 10, e1001577.	8.4	354
3	Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney International, 2018, 93, 941-951.	5.2	139
4	Mechanisms, Clinical Implications, and Treatment of Intradialytic Hypotension. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1297-1303.	4.5	98
5	Autogenous versus prosthetic vascular access for hemodialysis: A systematic review and meta-analysis. Journal of Vascular Surgery, 2008, 48, S34-S47.	1.1	96
6	Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients. Kidney International, 2012, 82, 204-211.	5.2	91
7	Dialysate sodium, serum sodium and mortality in maintenance hemodialysis. Nephrology Dialysis Transplantation, 2012, 27, 1613-1618.	0.7	86
8	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1236-1245.	1.6	81
9	Estimated glomerular filtration rate and urine biomarkers in patients with single-ventricle Fontan circulation. Heart, 2017, 103, 434-442.	2.9	55
10	Surveillance of arteriovenous hemodialysis access: A systematic review and meta-analysis. Journal of Vascular Surgery, 2008, 48, S48-S54.	1.1	53
11	Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 531-541.	4.5	43
12	Association of Predialysis Calculated Plasma Osmolarity With Intradialytic Blood Pressure Decline. American Journal of Kidney Diseases, 2015, 66, 499-506.	1.9	41
13	Iron, Hcpidin, and Death in Human AKI. Journal of the American Society of Nephrology: JASN, 2019, 30, 493-504.	6.1	41
14	Association of serum sodium with morbidity and mortality in hospitalized patients undergoing major orthopedic surgery. Journal of Hospital Medicine, 2014, 9, 297-302.	1.4	40
15	Dialysate Sodium: Rationale for Evolution over Time. Seminars in Dialysis, 2017, 30, 99-111.	1.3	37
16	Serum uric acid, influence of sacubitrilâ€“valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: <sc>PARAGONâ€“HF</sc>. European Journal of Heart Failure, 2020, 22, 2093-2101.	7.1	33
17	Excess mortality in solid organ transplant recipients hospitalized with COVIDâ€“19: A largeâ€“scale comparison of SOT recipients hospitalized with or without COVIDâ€“19. Clinical Transplantation, 2022, 36, e14492.	1.6	33
18	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2016, 68, 873-881.	1.9	28

#	ARTICLE	IF	CITATIONS
19	Intradialytic Hypotension and Cardiac Arrhythmias in Patients Undergoing Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 805-812.	4.5	26
20	Osmolality and blood pressure stability during hemodialysis. <i>Seminars in Dialysis</i> , 2017, 30, 509-517.	1.3	24
21	Lyme disease-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3054-3056.	0.7	23
22	Comparison of Urine Output among Patients Treated with More Intensive Versus Less Intensive RRT: Results from the Acute Renal Failure Trial Network Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1335-1342.	4.5	23
23	Incidence and causes of in-hospital outcomes and 30-day readmissions after percutaneous left atrial appendage closure: A US nationwide retrospective cohort study using claims data. <i>Heart Rhythm</i> , 2020, 17, 374-382.	0.7	23
24	Association of Prediabetes With CKD Progression and Adverse Cardiovascular Outcomes: An Analysis of the CRIC Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1772-e1780.	3.6	23
25	Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 374-382.	4.1	23
26	Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. <i>JACC: Heart Failure</i> , 2021, 9, 13-24.	4.1	22
27	Marital status, dipping and nocturnal blood pressure. <i>Journal of Hypertension</i> , 2014, 32, 756-761.	0.5	19
28	Creatinine versus cystatin C to estimate glomerular filtration rate in adults with congenital heart disease: Results of the Boston Adult Congenital Heart Disease Biobank. <i>American Heart Journal</i> , 2019, 214, 142-155.	2.7	19
29	Filter clotting with continuous renal replacement therapy in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 966-970.	2.1	19
30	Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008597.	3.9	19
31	The relevance of dietary sodium in hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 797-802.	0.7	18
32	Association of Albuminuria With Major Adverse Outcomes in Adults With Congenital Heart Disease. <i>JAMA Cardiology</i> , 2018, 3, 308.	6.1	18
33	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019, 73, 309-315.	1.9	18
34	Optimal Dialysate Sodium—What is the Evidence?. <i>Seminars in Dialysis</i> , 2014, 27, 128-134.	1.3	17
35	Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 32-41.	1.9	17
36	Predictors of Intradialytic Symptoms: An Analysis of Data From the Hemodialysis Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 331-339.	1.9	17

#	ARTICLE	IF	CITATIONS
37	Timing of referral for vascular access placement: A systematic review. <i>Journal of Vascular Surgery</i> , 2008, 48, S31-S33.	1.1	15
38	Impaired Fasting Glucose and Chronic Kidney Disease, Albuminuria, or Worsening Kidney Function: A Secondary Analysis of SPRINT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4024-4032.	3.6	15
39	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. <i>Circulation</i> , 2021, 143, 949-958.	1.6	15
40	Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from <sc>PARAGONâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 794-803.	7.1	15
41	Association of Smoking with Cardiovascular and Infection-Related Morbidity and Mortality in Chronic Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1827-1835.	4.5	14
42	Preservation of Blood Pressure Stability with Hypertonic Mannitol during Hemodialysis Initiation. <i>American Journal of Nephrology</i> , 2012, 36, 168-174.	3.1	14
43	Lower urine sodium predicts longer length of stay in acute heart failure patients: Insights from the ROSE AHF trial. <i>Clinical Cardiology</i> , 2020, 43, 43-49.	1.8	14
44	<sc>Angiotensinâ€neprilysin</sc> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.	7.1	14
45	Intensive Blood Pressure Treatment Reduced Stroke Risk in Patients With Albuminuria in the SPRINT Trial. <i>Stroke</i> , 2019, 50, 3639-3642.	2.0	12
46	Hypertonic Mannitol for the Prevention of Intradialytic Hypotension: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 483-490.	1.9	9
47	Renal Allograft Rupture: A Strategy for Graft Preservation. <i>Transplantation</i> , 2011, 91, e67-e69.	1.0	8
48	Change in Hemoglobin Trajectory and Darbeoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017, 46, 488-497.	3.1	8
49	Association of Different Definitions of Intradialytic Hypertension With Long-Term Mortality in Hemodialysis. <i>Hypertension</i> , 2022, 79, 855-862.	2.7	8
50	Dialysate Sodium and the Milieu IntÃ©rieur. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 5-7.	4.5	7
51	Serum Magnesium, Blood Pressure, and Risk of Hypertension and Chronic Kidney Disease Progression in the CRIC Study. <i>Hypertension</i> , 2021, 78, 1771-1780.	2.7	7
52	Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e281-e292.	3.6	6
53	Electrolyte Changes in Contemporary Hemodialysis: A Secondary Analysis of the Monitoring in Dialysis Study. <i>Kidney360</i> , 2021, 2, 695-707.	2.1	5
54	Race, Plasma Renin Activity, and Morning Blood Pressure Surge--Results From the Dietary Approaches to Stop Hypertension Trial. <i>American Journal of Hypertension</i> , 2014, 27, 530-536.	2.0	4

#	ARTICLE	IF	CITATIONS
55	A randomized controlled trial of two dialysate sodium concentrations in hospitalized hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.7	4
56	Urinary Sodium as a Heart Failure Biomarker. <i>JACC: Heart Failure</i> , 2019, 7, 415-417.	4.1	3
57	Endothelin-1 and Parameters of Systolic Blood Pressure in Hemodialysis. <i>American Journal of Hypertension</i> , 2021, 34, 1203-1208.	2.0	3
58	Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. <i>Kidney360</i> , 2020, 1, 1380-1389.	2.1	2
59	Leveraging Deep Learning to Improve Safety of Outpatient Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 343-344.	4.5	2
60	Serum Sodium, Patient Symptoms, and Clinical Outcomes in Hospitalized Patients with COVID-19. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192110673.	2.1	2
61	Implantable cardioverter defibrillators in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 357-358.	9.6	1
62	Serum Myeloperoxidase, Uric Acid, and the Risk of Atrial Fibrillation in Chronic Kidney Disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009483.	4.8	1
63	Specific Electrocardiograph Intervals Predict Hospitalization with Atrial Fibrillation in Those with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2021, 52, 412-419.	3.1	1
64	Predialysis serum phosphate and intradialytic hypotension. <i>Hemodialysis International</i> , 2021, , .	0.9	1
65	Risk of Intradialytic Hypotension by Day of the Week in Maintenance Hemodialysis. <i>ASAIO Journal</i> , 2022, 68, 865-873.	1.6	1
66	Temporal Changes in Electrolytes, Acid-Base, QTc Duration, and Point-of-Care Ultrasound During Inpatient Hemodialysis Sessions. <i>Kidney360</i> , 0, , 10.34067/KID.0001652022.	2.1	1
67	In response to Association of serum sodium with morbidity and mortality in hospitalized patients undergoing major orthopedic surgery. <i>Journal of Hospital Medicine</i> , 2014, 9, 613-613.	1.4	0
68	Marriage and nocturnal blood pressure. <i>Journal of Hypertension</i> , 2014, 32, 1722.	0.5	0
69	SO087RISK OF INTRADIALYTIC HYPOTENSION BY DAY OF THE WEEK IN MAINTENANCE HEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
70	Dialysate Sodium One Size Unlikely to Fit All. <i>Kidney and Dialysis</i> , 2021, 1, 135-137.	1.0	0
71	Abstract 17176: Burden and Prognostic Importance of Heart Failure Signs and Symptoms - Differences in Heart Failure With Preserved versus Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, .	1.6	0
72	Abstract 17063: Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure. <i>Circulation</i> , 2020, 142, .	1.6	0